AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19840300 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mix (Bifidobacterium bifidum BGN4, B. lactis AD011, Lactobacillus acidophilus AD031)
Number of subjects: 68
Study 19840300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 18492366 — intervention group
Group type: EXPERIMENTAL
Intervention: Short GnRH agonist protocol with buserelin nasal sprays from day 2 and recombinant FSH from day 5
Number of subjects: 240
Study 18492366 — intervention group
Group type: COMPARATOR
Intervention: Long GnRH agonist protocol with buserelin from previous mid-luteal phase and recombinant FSH after down-regulation
Number of subjects: 240
Study 16466179 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Jianpi Huayu Decoction (YJHD)
Number of subjects: 43
Study 16466179 — intervention group
Group type: COMPARATOR
Intervention: Coated aldehyde oxystarch (control)
Number of subjects: 43
Study 12642847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 48
Study 12642847 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 48
Study 12642847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10434785 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8919897 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (NO) at a concentration of 30 ppm
Number of subjects: 20
Study 8919897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhalation of NO)
Number of subjects: 20
Study 1882901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (1 g q.i.d. for a maximum of 3 weeks)
Number of subjects: 60
Study 1882901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7051805 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PAM
Number of subjects: 293
Study 7051805 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP
Number of subjects: 293
Study 7051805 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP with radiation therapy
Number of subjects: 293
Study 7051805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 293
Study 7051805 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelosuppression levels
Number of subjects: 293
Study 29140831 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC-201 (13 g Hb/dL)
Number of subjects: 236
Study 29140831 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cells (pRBCs) (24 g Hb/dL)
Number of subjects: 236
Study 29140831 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC-201
Number of subjects: 236
Study 29140831 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cells (pRBCs)
Number of subjects: 236
Study 29140831 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme (10 g Hb/dL)
Number of subjects: 236
Study 29140831 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme
Number of subjects: 236
Study 29038962 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lag screws
Number of subjects: 318
Study 29038962 — intervention group
Group type: COMPARATOR
Intervention: Traditional miniplates
Number of subjects: 318
Study 27704143 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofile assay
Number of subjects: 155
Study 27704143 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype arm
Number of subjects: 155
Study 24432009 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory-reasoning group
Number of subjects: 209
Study 24432009 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory-reasoning group
Number of subjects: 209
Study 24432009 — intervention group
Group type: COMPARATOR
Intervention: Active control game group
Number of subjects: 209
Study 24432009 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 209
Study 21878488 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere damage (RHD)
Number of subjects: 28
Study 21878488 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere damage (LHD)
Number of subjects: 28
Study 21878488 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 18632252 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial questionnaire concerning screening for diabetes (experimental group)
Number of subjects: 964
Study 18632252 — intervention group
Group type: COMPARATOR
Intervention: No initial questionnaire (control group)
Number of subjects: 964
Study 17620655 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg/d)
Number of subjects: 1202
Study 17620655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1202
Study 15134988 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 2 mg
Number of subjects: 62
Study 15134988 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 3 mg
Number of subjects: 62
Study 15134988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11915639 — intervention group
Group type: EXPERIMENTAL
Intervention: ORABASE Soothe.N.Seal
Number of subjects: 0
Study 11915639 — intervention group
Group type: COMPARATOR
Intervention: Topical analgesics or systemic pain medications
Number of subjects: 0
Study 9517578 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol combined with flunisolide (1 mg every 10 min for 3 hours)
Number of subjects: 94
Study 9517578 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol and placebo (n = 47)
Number of subjects: 94
Study 7923304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/d
Number of subjects: 25
Study 7923304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/d
Number of subjects: 25
Study 7923304 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 25
Study 7923304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin and Pravastatin
Number of subjects: 25
Study 7923304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 25
Study 7923304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, Simvastatin, Pravastatin, Fluvastatin
Number of subjects: 25
Study 3354811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen insufflation during laryngoscopy with an Oxyscope laryngoscope blade
Number of subjects: 20
Study 3354811 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopy without oxygen insufflation
Number of subjects: 20
Study 1405349 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration (UF) at a rate of 1 to 1.5 liter/hr
Number of subjects: 12
Study 1405349 — intervention group
Group type: COMPARATOR
Intervention: UF combined with bicarbonate hemodialysis (UF + HD)
Number of subjects: 12
Study 845787 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure at a task
Number of subjects: 0
Study 845787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior failure in depressed male subjects
Number of subjects: 0
Study 845787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior failure in nondepressed male subjects
Number of subjects: 0
Study 31462579 — intervention group
Group type: EXPERIMENTAL
Intervention: Any webpage (chemical names only, names with quantity ranges, names with visual risk indicators)
Number of subjects: 1441
Study 31462579 — intervention group
Group type: EXPERIMENTAL
Intervention: Any webpage
Number of subjects: 1441
Study 31462579 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual risk indicator
Number of subjects: 1441
Study 31462579 — intervention group
Group type: COMPARATOR
Intervention: No webpage
Number of subjects: 1441
Study 31465093 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 333
Study 31465093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus daily vistusertib
Number of subjects: 333
Study 31465093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus intermittent vistusertib
Number of subjects: 333
Study 31465093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus everolimus
Number of subjects: 333
Study 29113664 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model (score 0-17) based on factors such as impaired performance status, pre-existing medical illness, elevated ALP, urea, hypoalbuminemia, and major hepatectomy.
Number of subjects: 2613
Study 29113664 — intervention group
Group type: COMPARATOR
Intervention: Validation of risk stratification model using Chi-square goodness-of-fit test.
Number of subjects: 2613
Study 25350224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin + Rosuvastatin
Number of subjects: 60
Study 25350224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin + Irbesartan
Number of subjects: 60
Study 24267513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - single dose of 2 grams
Number of subjects: 238
Study 24267513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 24267513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 238
Study 21282444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of solithromycin (50 to 1,600 mg)
Number of subjects: 0
Study 21282444 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven oral daily doses of solithromycin (200 to 600 mg)
Number of subjects: 0
Study 21282444 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of solithromycin (400 mg) with food
Number of subjects: 0
Study 21282444 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose regimens of solithromycin
Number of subjects: 0
Study 19815268 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 20 mg per day (n=243)
Number of subjects: 481
Study 19815268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=238)
Number of subjects: 481
Study 17187417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 3 months
Number of subjects: 71
Study 17187417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 14985603 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling service by the American Cancer Society
Number of subjects: 0
Study 11465334 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power holmium laser (25 W)
Number of subjects: 80
Study 11465334 — intervention group
Group type: COMPARATOR
Intervention: Full-power holmium laser (80 W)
Number of subjects: 80
Study 9779681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebox stimulation applied daily for 3 days using a negatively charged probe electrode, at pulse duration of 100 microsec, amplitude of 160 microamp, and frequency of 3000 Hz.
Number of subjects: 30
Study 9779681 — intervention group
Group type: COMPARATOR
Intervention: Placebo Rebox stimulation.
Number of subjects: 30
Study 9779681 — intervention group
Group type: COMPARATOR
Intervention: Active Rebox stimulation.
Number of subjects: 30
Study 7827943 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 g wheat fibre (Trifyba) daily for 12 weeks
Number of subjects: 38
Study 7827943 — intervention group
Group type: COMPARATOR
Intervention: 60 ml lactulose daily for 12 weeks
Number of subjects: 38
Study 3335948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent regimen (60 mg/m2/day for 4 weeks, followed by 40 mg/m2/day on 3 days a week for 4 weeks)
Number of subjects: 46
Study 3335948 — intervention group
Group type: COMPARATOR
Intervention: Long-term tapering regimen (60 mg/m2/day for 4 weeks, followed by the same dose on alternate days for 4 weeks and tapering by 10 mg/m2 on alternate days every 4 weeks for 5 months)
Number of subjects: 46
Study 29617889 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 3508
Study 29617889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3508
Study 29218126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-resectoscope
Number of subjects: 60
Study 29218126 — intervention group
Group type: COMPARATOR
Intervention: Conventional resectoscope
Number of subjects: 60
Study 29218126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 26077412 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week) or Adalimumab (40 mg/2 week) subcutaneously for 1 year
Number of subjects: 89
Study 26077412 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 89
Study 23219284 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril and hydrochlorothiazide
Number of subjects: 11582
Study 23219284 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril and amlodipine
Number of subjects: 11582
Study 21605608 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg kg⁻¹ BM
Number of subjects: 12
Study 21605608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 19598210 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption (>=50 g of alcohol daily)
Number of subjects: 10920
Study 19598210 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular heavy drinking (>=4 drinks daily on >=5 days per week)
Number of subjects: 10920
Study 19598210 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking >=50 g of alcohol daily in the finasteride arm
Number of subjects: 10920
Study 16452559 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (3 mg daily for 8 weeks)
Number of subjects: 68
Study 16452559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16452559 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 68
Study 15367067 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive tie condition
Number of subjects: 82
Study 15367067 — intervention group
Group type: COMPARATOR
Intervention: Acquaintance condition
Number of subjects: 82
Study 10879554 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2500
Study 10879554 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty-stent (CAS)
Number of subjects: 2500
Study 10879554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CEA and CAS
Number of subjects: 2500
Study 8652810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 10 days after first cycle)
Number of subjects: 589
Study 8652810 — intervention group
Group type: COMPARATOR
Intervention: Standard timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 14 days or later after first cycle)
Number of subjects: 589
Study 1310656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)‐coated APR Total Hip Replacement
Number of subjects: 0
Study 1310656 — intervention group
Group type: COMPARATOR
Intervention: Press‐fit only control group
Number of subjects: 0
Study 6202993 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy (twice a week for 24 weeks)
Number of subjects: 191
Study 6202993 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 191
Study 30487976 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVEdiabetes intervention (personalized consultations by dietitians, pedometers, monthly WhatsApp messages)
Number of subjects: 232
Study 30487976 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 232
Study 30487976 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVEdiabetes intervention
Number of subjects: 232
Study 28534446 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental-Moderate (EXP-Mod) diet
Number of subjects: 3
Study 28534446 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental-High (EXP-High) diet with 1000 mg n-3 fatty acids per serving
Number of subjects: 3
Study 28534446 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) diet from the US Military's Standard Garrison Dining Facility Menu
Number of subjects: 3
Study 26268058 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA)
Number of subjects: 49
Study 26268058 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGla)
Number of subjects: 49
Study 23899653 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplement
Number of subjects: 54
Study 23899653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 21036279 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 40
Study 21036279 — intervention group
Group type: COMPARATOR
Intervention: Microdiskectomy
Number of subjects: 40
Study 18771508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery (VD)
Number of subjects: 12
Study 18771508 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section delivery (CSD)
Number of subjects: 12
Study 15947629 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser bladder neck incision (HoBNI)
Number of subjects: 40
Study 15947629 — intervention group
Group type: COMPARATOR
Intervention: Holmium enucleation of the prostate (HoLEP)
Number of subjects: 40
Study 15947629 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of HoBNI and HoLEP
Number of subjects: 40
Study 12531939 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 144
Study 12531939 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 144
Study 10426331 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide tablets (800 to 1,200 mg/day)
Number of subjects: 42
Study 10426331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7500451 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bladder irrigation with 50 mg/l amphotericin B infused during 24 hours for 2 days
Number of subjects: 20
Study 7500451 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bladder irrigations of 10 mg/100 ml amphotericin B in 1 day
Number of subjects: 20
Study 2104135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (A/Cl) for 10 days
Number of subjects: 80
Study 2104135 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (TMP) for 10 days
Number of subjects: 80
Study 2104135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (A/Cl) for 3 days
Number of subjects: 80
Study 2104135 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (TMP) as a single dose
Number of subjects: 80
Study 6105556 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 768
Study 6105556 — intervention group
Group type: COMPARATOR
Intervention: No surgery (medical treatment)
Number of subjects: 768
Study 31836291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lavage with 50 mL of 0.2% bupivacaine
Number of subjects: 106
Study 31836291 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 106
Study 31718439 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided revascularization
Number of subjects: 216
Study 31718439 — intervention group
Group type: COMPARATOR
Intervention: Angiography guided
Number of subjects: 216
Study 31718439 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred lesions based on FFR
Number of subjects: 216
Study 31718439 — intervention group
Group type: COMPARATOR
Intervention: Angiography guided percutaneous coronary intervention
Number of subjects: 216
Study 28353221 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN-free regimens (sofosbuvir + ledipasvir with or without ribavirin)
Number of subjects: 43
Study 28353221 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN-containing treatment
Number of subjects: 43
Study 25886874 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 10/30/60 mg
Number of subjects: 761
Study 25886874 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg
Number of subjects: 761
Study 25886874 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 761
Study 23536466 — intervention group
Group type: EXPERIMENTAL
Intervention: L-protocol (lengthening exercises)
Number of subjects: 75
Study 23536466 — intervention group
Group type: COMPARATOR
Intervention: C-protocol (conventional exercises)
Number of subjects: 75
Study 21236405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C applied on the perilimbal sclera (sclera group)
Number of subjects: 56
Study 21236405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C applied under conjunctiva (subconjunctiva group)
Number of subjects: 56
Study 19185400 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1,200 mg) and vitamin D(3) (800 IU) supplementation
Number of subjects: 639
Study 19185400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study 17539788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical IOL Z9001
Number of subjects: 124
Study 17539788 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofocal IOL SA60AT
Number of subjects: 124
Study 17539788 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL SA40N
Number of subjects: 124
Study 15355651 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachy-chemotherapy group (n = 18)
Number of subjects: 36
Study 15355651 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 36
Study 11493740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight HES preparation (6% HES, MW 70,000)
Number of subjects: 40
Study 11493740 — intervention group
Group type: COMPARATOR
Intervention: Gelatin (3% gelatin, MW 35,000)
Number of subjects: 40
Study 11493740 — intervention group
Group type: COMPARATOR
Intervention: Medium-molecular-weight HES preparation (6% HES, MW 200,000/0.5)
Number of subjects: 40
Study 11493740 — intervention group
Group type: COMPARATOR
Intervention: High-molecular-weight HES preparation (6% HES, MW 450,000/0.7)
Number of subjects: 40
Study 9615959 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy focusing on respiration, loudness, articulation, prosody, and intonation
Number of subjects: 0
Study 9093728 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of oral 5-HT3 antagonists (ondansetron 8 mg b.i.d. or dolasetron 200 mg daily) plus dexamethasone 8 mg p.o. daily
Number of subjects: 407